Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 28:190:172-81.
doi: 10.1016/j.jconrel.2014.06.043. Epub 2014 Jul 3.

Ocular delivery of macromolecules

Yoo Chun Kim  1 , Bryce Chiang  2 , Xianggen Wu  3 , Mark R Prausnitz  4
Affiliations
Review

Ocular delivery of macromolecules

Yoo Chun Kim et al. J Control Release. .

Abstract

Biopharmaceuticals are making increasing impact on medicine, including treatment of indications in the eye. Macromolecular drugs are typically given by physician-administered invasive delivery methods, because non-invasive ocular delivery methods, such as eye drops, and systemic delivery, have low bioavailability and/or poor ocular targeting. There is a need to improve delivery of biopharmaceuticals to enable less-invasive delivery routes, less-frequent dosing through controlled-release drug delivery and improved drug targeting within the eye to increase efficacy and reduce side effects. This review discusses the barriers to drug delivery via various ophthalmic routes of administration in the context of macromolecule delivery and discusses efforts to develop controlled-release systems for delivery of biopharmaceuticals to the eye. The growing number of macromolecular therapies in the eye needs improved drug delivery methods that increase drug efficacy, safety and patient compliance.

Keywords: Barriers; Controlled release; Drug delivery; Eye; Macromolecules; Targeting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anatomy of the eye.
See this image and copyright information in PMC

References

    1. Ryu JK, Kim HS, Nam DH. Current status and perspectives of biopharmaceutical drugs. Biotechnol Bioprocess Eng. 2012;17:900–911.
    1. Aggarwal RS. What’s fueling the biotech engine-2012 to 2013. Nat Biotechnol. 2014;32:32–39. - PubMed
    1. Syed BA, Evans JB, Bielory L. Wet AMD market. Nat Rev Drug Discov. 2012;11:827. - PubMed
    1. El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res. 2010;29:443–465. - PubMed
    1. Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014 - PubMed

Publication types